Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FLGCNASDAQ:PHXMNASDAQ:QLGNNASDAQ:SNSE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFLGCFlora Growth$0.68-1.0%$0.58$0.42▼$2.11$13.20M2.01280,544 shs96,452 shsPHXMPHAXIAM Therapeutics$3.10$3.10$2.50▼$13.00$10.58M2.352,472 shsN/AQLGNQualigen Therapeutics$3.59$3.33$2.85▼$29.44$2.64M-0.07113,257 shs2,721 shsSNSESensei Biotherapeutics$0.36-4.4%$0.40$0.25▼$1.78$9.08M0.19910,190 shs130,221 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFLGCFlora Growth-4.11%+7.76%+38.55%-20.13%-55.34%PHXMPHAXIAM Therapeutics0.00%0.00%0.00%0.00%0.00%QLGNQualigen Therapeutics-0.03%0.00%+12.75%+10.12%-74.38%SNSESensei Biotherapeutics-3.23%-15.13%+15.02%-26.32%-80.43%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFLGCFlora Growth3.098 of 5 stars3.35.00.00.02.80.81.3PHXMPHAXIAM TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AQLGNQualigen TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ASNSESensei Biotherapeutics4.4702 of 5 stars3.65.00.04.80.91.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFLGCFlora Growth 2.67Moderate Buy$5.00636.49% UpsidePHXMPHAXIAM Therapeutics 0.00N/AN/AN/AQLGNQualigen Therapeutics 0.00N/AN/AN/ASNSESensei Biotherapeutics 3.25Buy$4.251,080.56% UpsideCurrent Analyst Ratings BreakdownLatest QLGN, FLGC, PHXM, and SNSE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/1/2025SNSESensei BiotherapeuticsStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/28/2025SNSESensei BiotherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$3.50 ➝ $4.003/28/2025SNSESensei BiotherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.00(Data available from 5/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFLGCFlora Growth$59.51M0.22N/AN/A$0.78 per share0.87PHXMPHAXIAM Therapeutics$32.66M0.32N/AN/A$7.98 per share0.39QLGNQualigen Therapeutics$4.98M0.53N/AN/A($20.31) per share-0.18SNSESensei BiotherapeuticsN/AN/AN/AN/A$2.60 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFLGCFlora Growth-$57.04M-$1.32N/AN/AN/A-30.99%-268.17%-57.51%5/13/2025 (Estimated)PHXMPHAXIAM Therapeutics-$240KN/A0.00∞N/AN/AN/AN/AN/AQLGNQualigen Therapeutics-$13.42MN/A0.00∞N/AN/AN/A-424.18%5/12/2025 (Estimated)SNSESensei Biotherapeutics-$34.10M-$1.15N/AN/AN/AN/A-53.86%-46.91%N/ALatest QLGN, FLGC, PHXM, and SNSE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025FLGCFlora Growth-$0.01N/AN/AN/A$14.79 millionN/A5/6/2025Q1 2025SNSESensei Biotherapeutics-$0.21-$0.27-$0.06-$0.27N/AN/A3/28/2025Q4 2024SNSESensei Biotherapeutics-$0.27-$0.27N/A-$0.31N/AN/A3/24/2025Q4 2024FLGCFlora Growth-$0.11-$0.42-$0.31-$0.45$13.55 million$13.33 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFLGCFlora GrowthN/AN/AN/AN/AN/APHXMPHAXIAM TherapeuticsN/AN/AN/AN/AN/AQLGNQualigen TherapeuticsN/AN/AN/AN/AN/ASNSESensei BiotherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFLGCFlora Growth0.431.020.64PHXMPHAXIAM Therapeutics0.231.78N/AQLGNQualigen TherapeuticsN/A0.520.52SNSESensei BiotherapeuticsN/A8.848.84Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFLGCFlora Growth36.01%PHXMPHAXIAM Therapeutics0.40%QLGNQualigen Therapeutics3.18%SNSESensei Biotherapeutics10.50%Insider OwnershipCompanyInsider OwnershipFLGCFlora Growth12.99%PHXMPHAXIAM Therapeutics1.94%QLGNQualigen Therapeutics1.80%SNSESensei Biotherapeutics23.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFLGCFlora Growth28019.44 million12.55 millionNot OptionablePHXMPHAXIAM Therapeutics493.41 million3.35 millionNo DataQLGNQualigen Therapeutics50736,000723,000Not OptionableSNSESensei Biotherapeutics4025.21 million19.62 millionNot OptionableQLGN, FLGC, PHXM, and SNSE HeadlinesRecent News About These CompaniesSensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical ProgressMay 6, 2025 | globenewswire.comSensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual ConferenceApril 2, 2025 | globenewswire.comSensei Biotherapeutics announces initial results from solnerstotug trial portionMarch 29, 2025 | markets.businessinsider.comSensei Rockets on FY ’24 ResultsMarch 29, 2025 | baystreet.caSensei Rockets on FY ’24 ResultsMarch 29, 2025 | baystreet.caSensei Biotherapeutics price target raised to $4 from $3.50 at OppenheimerMarch 29, 2025 | markets.businessinsider.comSensei Biotherapeutics price target raised to $4 from $3.50 at OppenheimerMarch 29, 2025 | markets.businessinsider.comSensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical ProgressMarch 28, 2025 | globenewswire.comSensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant TumorsMarch 27, 2025 | globenewswire.comWhat Makes Sensei Biotherapeutics (SNSE) a New Buy StockFebruary 6, 2025 | zacks.comSensei Biotherapeutics to Participate in Oppenheimer’s 35th Annual Healthcare Life Sciences ConferenceFebruary 4, 2025 | markets.businessinsider.comSensei Biotherapeutics to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences ConferenceFebruary 4, 2025 | globenewswire.comSensei Biotherapeutics Inc (SNSE) Stock: Unveiling Its Hidden StrengthsJanuary 18, 2025 | bovnews.comSensei Biotherapeutics provides update, highlights key upcoming milestonesJanuary 9, 2025 | markets.businessinsider.comPromising Outlook for Sensei Biotherapeutics: Buy Rating Backed by SNS-101 Development and Financial ProjectionsJanuary 9, 2025 | markets.businessinsider.comSensei Biotherapeutics Inc (SNSE) Stock Trading RecapJanuary 9, 2025 | bovnews.comSensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming MilestonesJanuary 8, 2025 | globenewswire.comSensei Biotherapeutics to Participate in Citi’s 2024 Global Healthcare ConferenceNovember 28, 2024 | markets.businessinsider.comSensei Biotherapeutics to Participate in Citi's 2024 Global Healthcare ConferenceNovember 27, 2024 | globenewswire.comSensei Biotherapeutics, Inc. (SNSE)November 20, 2024 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeQLGN, FLGC, PHXM, and SNSE Company DescriptionsFlora Growth NASDAQ:FLGC$0.68 -0.01 (-1.03%) As of 05/9/2025 04:00 PM EasternFlora Growth Corp., together with its subsidiaries, engages in the growth, cultivation, and development of medicinal cannabis and medicinal cannabis derivative products worldwide. It operates through three segments: House of Brands, Commercial and Wholesale, and Pharmaceuticals. The company cultivates, processes, and supplies medicinal-grade cannabis flower, and cannabis derived medical and wellness products. It also offers food and beverage, nutraceuticals, cannabis accessories and technology, personal care, and wellness; cannabidiol (CBD) derived products, such as gummies, topicals, tinctures, and vape products; cannabis consumption accessories, personal storage, and travel accessories for the vape and dry herbs. In addition, the company manufactures and distributes pharmaceutical goods and medical cannabis products to treat a variety of health indications, including drugs related to cancer therapies, attention-deficit/hyperactivity disorder, multiple sclerosis, and anti-depressants. The company sells its products under the JustCBD, Vessel, and Phatebo brands. Flora Growth Corp. was incorporated in 2019 and is based in Fort Lauderdale, Florida.PHAXIAM Therapeutics NASDAQ:PHXM$3.10 0.00 (0.00%) As of 05/9/2025PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.Qualigen Therapeutics NASDAQ:QLGN$3.59 0.00 (0.00%) As of 05/9/2025 02:47 PM EasternQualigen Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.Sensei Biotherapeutics NASDAQ:SNSE$0.36 -0.02 (-4.41%) As of 05/9/2025 04:00 PM EasternSensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs Why Nearly 20 Analysts Raised Meta Price Targets Post-Earnings Strategists Say Hold: Stocks May Beat the 'Sell in May' Trend Here's The Reason Goldman Sachs Is Bullish On MercadoLibre Stock GlobalFoundries Stock Hits Bottom: Is a Rebound Coming? What the ExtraHop Deal Means for CrowdStrike DoorDash’s Uptrend Is Gaining Momentum in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
